Total debt of roughly $33.6M against equity of $143.6M yields a D/E of 0.23, which appears modest, but this headline ratio may understate risk as equity shrank from $458.8M in 2024Q1 and cash fell to $24.8M.
Zentalis Pharmaceuticals, Inc. (ZNTL) balance sheet — 8-year assets, liabilities & shareholders' equity history
| Metric | TTM | Dec'25 | Dec'24 | Dec'23 | Dec'22 | Dec'21 | Dec'20 | Dec'19 | Dec'18 |
|---|
| Total Current Assets | 237.27M | 253.19M | 386.07M | 496.72M | 451.93M | 350.77M | 345.1M | 68.89M | 26.68M |
| Cash & Short-Term Investments | 228.89M | 245.89M | 371.08M | 482.92M | 437.37M | 340.13M | 338.5M | 67.25M | 25.15M |
| Cash Only | 24.03M | 35.99M | 33.9M | 28.04M | 43.07M | 59.96M | 54.95M | 67.25M | 25.15M |
| Short-Term Investments | 204.86M | 209.9M | 337.18M | 454.88M | 394.3M | 280.17M | 283.55M | 0 | 0 |
| Accounts Receivable | 0 | 1.93M | 5M | 0 | 0 | 2.63M | 0 | 140K | 917K |
| Days Sales Outstanding | - | - | 27.07 | - | - | - | - | - | 23.91K |
| Inventory | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Days Inventory Outstanding | - | - | - | - | - | - | - | - | - |
| Other Current Assets | 0 | 5.37M | 0 | 13.8M | 14.56M | 0 | 417K | 0 | 0 |
| Total Non-Current Assets | 32.92M | 35.78M | 44.27M | 65.31M | 101.52M | 121.25M | 20.45M | 19.34M | 14.32M |
| Property, Plant & Equipment | 26.18M | 29.04M | 37.23M | 41.73M | 50.08M | 52.84M | 3.62M | 2.84M | 260K |
| Fixed Asset Turnover | 0.00x | - | 1.81x | - | - | - | - | - | 0.05x |
| Goodwill | 0 | 0 | 0 | 3.74M | 3.74M | 3.74M | 3.74M | 3.74M | 3.74M |
| Intangible Assets | 0 | 0 | 0 | 0 | 0 | 0 | 8.8M | 8.8M | 8.8M |
| Long-Term Investments | 5.25M | 0 | 2.63M | 2.68M | 23.84M | 40.12M | 0 | 243K | -46.26K |
| Other Non-Current Assets | 6.74M | 6.74M | 4.42M | 6.82M | 9.72M | 7.04M | 4.3M | 2.97M | 1.52M |
| Total Assets | 270.19M | 288.97M | 430.34M | 562.03M | 553.46M | 472.02M | 365.56M | 88.23M | 41M |
| Asset Turnover | 0.00x | - | 0.16x | - | - | - | - | - | 0.00x |
| Asset Growth % | -123.16% | -32.85% | -23.43% | 1.55% | 17.25% | 29.13% | 314.31% | 115.21% | - |
| Total Current Liabilities | 32.36M | 36.56M | 52.73M | 69.37M | 56.65M | 43.94M | 28.6M | 14.9M | 6.21M |
| Accounts Payable | 5.33M | 7.21M | 7.44M | 14.93M | 11.25M | 11.59M | 8.66M | 4.29M | 3.43M |
| Days Payables Outstanding | 16.96K | - | - | - | - | - | - | - | - |
| Short-Term Debt | 0 | 3.87M | 3.07M | 2.62M | 0 | 1.45M | 0 | 781K | 0 |
| Deferred Revenue (Current) | 0 | 0 | 0 | 281K | 0 | 0 | 0 | 0 | 223.42K |
| Other Current Liabilities | 0 | 15.51M | 29.42M | -2.9M | 384K | 20.68M | 410K | 6.85M | 223K |
| Current Ratio | 7.33x | 6.93x | 7.32x | 7.16x | 7.98x | 7.98x | 12.07x | 4.62x | 4.30x |
| Quick Ratio | 7.33x | 6.93x | 7.32x | 7.16x | 7.98x | 7.98x | 12.07x | 4.62x | 4.30x |
| Cash Conversion Cycle | - | - | - | - | - | - | - | - | - |
| Total Non-Current Liabilities | 32.94M | 36.2M | 40.43M | 55.27M | 62.79M | 63.6M | 3.58M | 4.91M | 2.48M |
| Long-Term Debt | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Capital Lease Obligations | 101.7M | 35.7M | 39.58M | 43.15M | 45.17M | 44.46M | 1.1M | 1.7M | 0 |
| Deferred Tax Liabilities | 0 | 0 | 0 | 10.34M | 15M | 19.14M | 0 | 3.21M | 2.46M |
| Other Non-Current Liabilities | 500K | 500K | 849K | 1.78M | 2.62M | 0 | 2.48M | 5K | 21K |
| Total Liabilities | 65.31M | 72.76M | 93.15M | 124.64M | 119.43M | 107.54M | 32.18M | 19.81M | 8.69M |
| Total Debt | 36.71M | 39.58M | 42.65M | 45.77M | 47.33M | 45.91M | 2M | 2.48M | 0 |
| Net Debt | 12.68M | 3.58M | 8.75M | 17.73M | 4.26M | -14.04M | -52.95M | -64.77M | -25.15M |
| Debt / Equity | 0.18x | 0.18x | 0.13x | 0.10x | 0.11x | 0.13x | 0.01x | 0.04x | - |
| Debt / EBITDA | -0.24x | - | - | - | - | - | - | - | - |
| Net Debt / EBITDA | -0.08x | - | - | - | - | - | - | - | - |
| Interest Coverage | - | - | - | - | -91.26x | - | - | - | - |
| Total Equity | 204.89M | 216.2M | 337.19M | 437.39M | 434.02M | 364.48M | 333.38M | 68.42M | 32.31M |
| Equity Growth % | -140.68% | -35.88% | -22.91% | 0.78% | 19.08% | 9.33% | 387.24% | 111.79% | - |
| Book Value per Share | 2.42 | 3.01 | 4.74 | 6.69 | 8.21 | 8.54 | 8.12 | 1.91 | 1.79 |
| Total Shareholders' Equity | 204.89M | 216.2M | 337.19M | 437.28M | 433.8M | 363.95M | 308.58M | 61.6M | 24.77M |
| Common Stock | 98K | 69K | 71K | 70K | 59K | 45K | 41K | 2.89M | 2.27M |
| Retained Earnings | -1.3B | -1.19B | -1.05B | -888.56M | -596.37M | -359.56M | -200.83M | -82.99M | -37.33M |
| Treasury Stock | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Accumulated OCI | -495K | 196K | 558K | 2.19M | -1.35M | -125K | 36K | 0 | -56K |
| Minority Interest | 0 | 0 | 0 | 107K | 221K | 528K | 24.8M | 6.82M | 7.54M |
Quick answers to the most common questions about buying ZNTL stock.
As of 2025, Zentalis Pharmaceuticals, Inc. (ZNTL) had total assets of $289.0M including $253.2M in current assets.
Zentalis Pharmaceuticals, Inc. (ZNTL) carries total debt of $39.6M, offset by $245.9M in cash and short-term investments. Comparing total debt to cash helps evaluate the company's debt burden and net leverage.
Zentalis Pharmaceuticals, Inc. (ZNTL) has total shareholders' equity (book value) of $216.2M ($3.01 book value per share). Book value represents the net worth of the company belonging to common stock holders.
Zentalis Pharmaceuticals, Inc. (ZNTL) reported a current ratio of 6.93x. A current ratio above 1.0x indicates that the company has more current assets than current liabilities, suggesting sufficient short-term liquidity.
Key Metrics
Top Statement Risk
Shrinking cash cushion against burn
Metrics are mathematically derived from official filings.
Asset Base Shrinking Steadily Over Time
According to the reported quarterly balance sheets, ZNTL's total assets fell from $557.5M in 2024Q1 to $215.3M in 2026Q2, a decline of roughly 61 percent that tracks the company's sustained operating losses.
The contraction is driven primarily by cash consumption rather than any asset repositioning, since goodwill was written off entirely and PPE has remained small. Equity has fallen from $458.8M to $143.6M over the same period, which suggests the balance sheet is weakening as a direct function of the burn rate. Investors should monitor whether the trajectory implies a need for external capital before the next clinical or regulatory milestone.
Current Ratio Masks Thinning Cash Runway
Based on reported figures, ZNTL's current ratio remains elevated at 4.82 in 2026Q2, yet cash has declined from $41.9M in 2025Q1 to $24.8M, leaving a much thinner buffer than the ratio alone implies.
A high current ratio here reflects the modest size of current liabilities relative to the remaining liquid base rather than a deep reservoir of cash. Given free cash flow in the range of negative $27M to negative $70M per quarter, the reported cash position may cover only a limited number of quarters of operating burn. This warrants further investigation into the timing of cash needs relative to the company's pipeline commitments.
Low Leverage Reflects Limited Borrowing Capacity
As reported in the financial statements, ZNTL's debt-to-equity ratio has risen from 0.10 to 0.23 while total debt stayed near $34M to $45M, indicating leverage is increasing mainly because equity is shrinking.
The rising D/E ratio is an artifact of equity erosion rather than new borrowing, which is a meaningful distinction for interpreting leverage. Modest absolute debt levels suggest the company has not relied heavily on credit to fund operations, but the absence of a larger debt base may also reflect constrained access to lenders for a loss-making biotech. The key monitoring point is whether declining equity eventually pressures debt covenants or refinancing terms.
Accumulated Deficit Dominates Equity Structure
Based on the reported retained earnings line, ZNTL's accumulated deficit deepened from -$878.5M in 2024Q1 to roughly -$1.3B in 2026Q2, which is the principal driver of the equity decline.
The equity base is being eroded almost entirely by cumulative losses, with stock-based compensation adding a non-cash component that is not captured in cash burn figures. Reported stock-based compensation of $31.4M in 2024Q4 and $6.4M in 2026Q2 indicates ongoing equity-linked cost that may imply future dilution. Investors should monitor share count changes as a potential transfer of value from existing holders.
Low Debt Is Not Balance Sheet Safety
Based on reported figures, ZNTL's modest D/E of 0.23 may appear reassuring, but the headline leverage ratio understates risk because the company's equity cushion and cash runway are both declining simultaneously.
A low leverage ratio can be misleading when the denominator, equity, is shrinking faster than debt is changing, and that dynamic is evident here. The more relevant risk is the combination of falling cash, persistent negative free cash flow, and the absence of reported revenue, which together suggest dependence on future financing. This is an analytical inference from the reported data rather than a disclosed fact about the company's funding plans.